Please use this identifier to cite or link to this item:
標題: 抗Indoleamine-2,3-Dioxygenase多株、單株及單鏈抗體之製備、分析及應用
Preparation, characterization and application of anti-human indoleamine-2,3-dioxygenase antibodies
作者: 黃雅芳
Huang, Ya-Fang
關鍵字: IIndoleamine-2,3-dioxygenase;Indoleamine-2,3-dioxygenase;Single-chain variable fragment;SKOV-3;Tryptophan;單鏈抗體;卵巢癌細胞;Tryptophan
出版社: 生物化學研究所
引用: 1. 江肇偉。(2003)。肺癌細胞株抗TRAIL誘導細胞凋亡。中山醫學大學毒理學研究所碩士論文 2. 林順富、葉東柏、陳師瑩、顏瑞鴻、蕭慧美。(2004)。生物化學。偉明圖書有限公司。 3. 姜維中。(2003)。構築並自抗體噬菌體展示系統中篩選出具有N-Acyl-L-homoserine lactone結合力的單鏈抗體。國立中興大學生物化學研究所碩士論文 4. 張東玄。(1987)。單株抗體及其應用。金台灣資訊事業有限公司。生物技術專輯 5. 張嘉文。(1998)。製造並分析抗Bromadiolone之抗體。國立中興大學生物化學研究所碩士論文 6. 莊榮輝。(2004)。生物技術概論。國立台灣大學生化科技學系生化研究室 7. 游丈樟、呂錦聰。癌症之標靶治療。藥學雜誌99期。25(2):125-130 8. 黎煥耀。(2002)。免疫系統。偉明圖書有限公司 9. Belladonna, M L., Volpi, C., Bianchi, R., Vacca, C., Orabona, C., Pallotta, M T., Boon, L., Gizzi, S., Fioretti, M C., Grohmann, U., Puccetti, P. (2008) Cutting edge:autocrine TGF-β sustains default tolerogenesis by IDO-competent dendritic cells. The Journal of Immunology 181:5194-5198 10. Braun, D., Longman, R S., Albert M L. (2005) A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 106(7):2375-2381 11. Chang, M Y., Boulden, J., Sutanto-Ward, E., Duhadaway, J B., Soler, A P., Muller, A J., Prendergast, G C.(2007) Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. Cancer Research 67(1):100-107 12. Cheng, C H., Lin, C L., Chen, Y H., Lin, Y H., Lin, J Y., Kao, J Y., Kao, M C., Way, T D. (2009) Indoleamine-2,3-dioxygenase, an immunomodulatory protein, is suppressed by (-)-Epigallocatechin-3-gallate via blocking of gamma-interferon induced JAK-PKC-δ-STAT1 signaling in human oral cancer cells. Journal of Agricultural and Food Chemistry 58:887-894 13. Frumento, G., Rotondo, R., Tonetti, M., Damonte, G., Benatti, U., Ferrara, G B. (2002) Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by Indoleamine 2,3-Dioxygenase. The Journal of Experimental Msdicine 196:459-468 14. Ge, K., Duhadaway, J., Du, W., Herlyn, M., Rodeck, U., Preenedrgast, G C. (1999)Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon cause loss of function of Bin1 in melanoma. Proceedings of the National Academy of Science 96:9689-9694 15. Ge, K., Duhadaway, J., Sakamuro, D., Wechsler-Reya, R., Prendergast, G C.(2000a) Losses of the tumor suppressor Bin1 in breast cancer are frequent and reflect deficits in programmed cell death capacity. International Union Against Cancer 85:376-383 16. Ge, K., Minhas, F., Duhadaway, J., Mao, N C., Wilson, D., Buccafusca, R., Sakamuro, D., Nelson, P., Malkowicz, S B., Tomaszewski, J., Prendergast, G C.(2000b) Losses of the heterozygosity tumor suppressor and tumor suppressor activity of Bin1 in prostate carcinoma. International Union Against Cancer 86:155-161 17. Hayaishi, T., Mo, J H., Gong, X., Rossetto, C., Jang, A., Beck, L., Elliott, G I., Kufareva, I., Abagyan, R., Broide, D H., Lee, J., Raz, E. (2007) 3-Hydroxyanthranilic acid inhibits PDK1 activiation and suppresses experimental asthma by inducing T cell apoptosis. Proceedings of the National Academy of Science 104(47):18619-18624 18. Holliger, P., Hudson P. (2005) Engineered antibody fragments and the rise of single domains. Nature biotechnology 23:1126-1136 19. Hoshi, M., Saito, K., Murakami, Y., Taguchi, A., Fujigaki, H., Tanaka, R., Takemura, M., Ito, H., Hara, A., Seishima, M. (2009)Marked increases in hippocampal neuron indoleamine 2,3-dioxygenase via IFN-γ -independent pathway following transient global ischemia in mouse. Neuroscience Research 63:194-198 20. Jeong, Y I., Kim, S W., Jung, I D., Lee, JS., Chang, J H., Lee, C M., Chun, S H., Yoon, M S., Kim, G T., Ryu, S W., Kim, J S., Shin, Y K., Lee, W S., Shin, H K., Lee. J D., Park, Y M. (2009) Curcumin suppression the induction of indoleamine 2,3-dioxygenase by blocking the janus-activated kinase-protein kinase C-δ-STAT1 signaling pathway interferon-γ-stimulated murine dendritic cells. Journal of Biological Chemistry 284(6):3700-3708 21. Jing, M A., Sun, J Y. Protein folding and the formation of inclusion bodies. (2004) Jouranol of Zhejiang University 30(6):690-696 22. Littlejohn, T K., Takikawa, O., Skylas, D., Jamie, J F., Walker, M J., Truscott, R J W. (2000) Expression and purification of recombinant human indoleamine 2,3-dioxygenase. Protein Expression and Purification 19:22-29 23. Lob, S., Konigsrainer, A., Rammensee, H G., Opelz, G., Terness, P. (2009) Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy:can we see the wood for the trees. Nature 9:445-452 24. Lopez, A S., Alegre, E., Diaz, A., Mugueta, C., Gonzalez, A. (2006) Bimodal effect of nitric oxide in the enzymatic activity of indoleamine 2,3-dioxygenase in human monocytic cells. Immunology Letters 106:163-171 25. Lucena, A P., Ho, C S W., Mao, D Y L., Sheng, Y., Laister, R C., Muhandiram, R., Seet, Y L B T., Katz, S., Szyperski, T., Penn, L S Z., Arroesmith, C H. (2005) A structure-based model of the c-Mys/ Bin1 protein interaction shows alternative splicing of BIN1 and c-Mys phosphorylation are key binding determinants. Journal of Molecular Biology 351:182-194 26. Male, D K., Pryce, G., Cooke, A., Hutchings, P., Clarke, S M., Roitt, I M. (1986) T and B Cell connections in experimentally induced autoimmunity. Immunology 475:94-105 27. Maynard, J., Georgiou, G. (2000) Antibody engineering. Annual review of biomedical engineering 2:339-336 28. Muller, A J., Duhadaway, J B., Donover, P S., Ward, E S., Prendergast, G C. (2005) Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy Nature Medicine 11(3):312-319 29. Munn, D H., John, M Z., Attwood J T., Bondarev, L., Conway, S J., Marshall, B., Brown, C., Mellor, A. (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 28:1191-1193 30. Munn, D H., Shafizadeh, E., Attwood, J T., Bondarev, I., Pashine, A., Mellor, A L. (1999) Inhibition of T cell proliferation by macrophage tryptophan catabolism. Journal of Experimental Msdicine 189:1363-1372 31. Munn, D H., Sharma, M D., Baban, B., Harding, H P., Zhang, Y., Ron, D., Mellor, A L. (2005) GCN2 kinase in T cells mediates proliferative arrest and anergy Induction in Response to indoleamine 2,3-Dioxygenase. Immunity 22:633-642 32. Munn, D H., Sharma, M D., Lee, J R., Jhaver, K G., Johnson, T S., Keskin, D B., Marshall, B., Chandler, P., Antonia, S J., Burgess, R., Jr, C L S., Mellor, A L. (2002) Potential regulatory function of human dendritic cells expressing indoleamine-2,3-dioxygenase. Seience 297:1867-1870 33. Nelson, B H. (2009) IDO and outcomes in ovarian cancer. Gynecologic oncology 115(2):179-180 34. Oda, S I., Sugimoto, H., Yoshida, T., Shiro, Y. (2006) Crystallization and preliminary crystallographic studies of human indoleamine 2,3-dioxygenase. Structural biology and crystallization communications. Acta Crystallographica Section F 62(3):221-223 35. Okuda, S., Nishiyama, N., Saito, H., Katsuki, H. (1996) Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine. Proceedings of the National Academy of Science 93: 12553-1255 36. Pearson, S J., Reynolds, G P. (1992) Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine. Neuroscience Letters 144:199-201 37. Pisano, M., Pagnan, G., Dettori, M A., Cossu, S., Caffa, I., Sassu, I., Emionite, L., Fabbri, D., Cilli, M., Pastorino, F., Palmieri, G.., Delogu, G., Ponzoni, M., Rozzo, C. (2010) Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells. Istituto di Chimica Biomolecolare 137(9):1-28 38. Sanni, L A. (2001) The role of cerebral oedema in the pathogenesis of cerebral malaria. Redox Report 6(3):137-142 39. Sugimoto, H., Oda, S., Otsuki, T., Hino, T., Yoshida, T., Shiro, Y. (2006) Crystal structure of human indoleamine-2,3-dioxygenase:catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proceedings of the National Academy of Science 103(8):2611-2616 40. Suzuki, Y., Suda, T., Furuhashi, K., Suzuki, M., Fujie, M., Hahimoto, D., Nakamura, Y., Inui, N., Nakamura, H., Chida, K. (2009)Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung cancer 3352:1-5 41. Tajiri, T., Lin, X., Thompson, P M., Tanaka, S., Suita, S., Zhao, H., Maris, J M., Prendergast, G C., Hogarty, M D. (2003) Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Clinical Cancer Research 9:3345-3355 42. Tan, P H., Bharath, A K. (2009) Manipulation of indoleamine-2,3-dioxygenase;a novel therapeutic target for treatment of disease. Expert Opin 13(8):987-1012 43. Tan, P L C H B., Kim, S A., Choi, H S., Yoon, J H., Ahn, G. (2010)Epigallocatechin-3-gallate suppresses the expression of HSP70 and HSP90 and exhibits anti-tumor activity in vitro and in vivo. BioMed Central cancer 267(10):1-30 44. Trimble, W S., Baker, M D., Boulianne, G L., Murialdo, H., Hozumi, N., Shulman, M J. (1986) Analysis of hybridoma mutans defective in synthesis of immunoglobulin M. Somatic Cell and Molecular Genetics 12:467-477 45. Wang, Q., Gao, Z X., Zhang, N., Shi, Y., Xie, X L., Chen, Q X. (2010) Purification and characterization of trypsin from the intestine of hybrid tilapia (Oreochromis niloticus O.aureus). Journal of Agricultural and Food Chemistry 58:655-659 46. Weisser, N E., Hall, J C. (2009) Applications of single-chain variable fragment antibodies in therapeutics and diagnostics. Biotechnology Advances 27:502-520 47. Yoshida, R., Hayaishi, O. (1978) Induction of pulmonary indoleamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide. Proceedings of the National Academy of Science 75(8):3998-4000 48. Yoshida, R., Urade, Y., Tokuda, M., Hayaishi, O. (1979) Induction of indoleamine 2,3-dioxygenase in mouse lung during virus infection. Proceedings of the National Academy of Science 76(8):4084-4086
由於IDO的大量表現會使得腫瘤細胞免於遭受免疫系統的攻擊,因此如能利用自身免疫系統來中和IDO的活性,則達到抗癌效果。本研究主要在製備抗Indoleamine 2,3-diogenase之多株抗體、單株抗體及單鏈抗體,期望能運用抗體與抗原結合的原理,中和IDO在體內的生物活性。本實驗使用卵巢癌細胞 (SKOV-3)以RT-PCR實驗選殖出ido基因,將選殖到原核表現質體pET-28a,以大腸桿菌表達目標蛋白his-IDO,利用親和性管柱純化IDO重組蛋白後,來免疫小鼠,製備抗his-IDO多株抗體,後利用融合瘤逐步稀釋技術來製造單株抗體。實驗結果發現,his-IDO重組蛋白可和抗his-IDO多株抗體及單株抗體做專一性的結合,此外也發現其效價高,可偵測到卵巢癌細胞(SKOV-3)中高度表現IDO。而單株融合瘤細胞之VH及VL以聚合酶連鎖反應技術篩選出來接上連接子(Linker),製成單鏈抗體cDNA(Single-chain variable fragment, scFv),期望未來可以運用在癌症醫療上作為輔助性治療之用。

Indoleamine-2,3-dioxygenase(IDO), an intracellular enzyme, catalyzes the rate-limiting step in tryptophan catabolism to the kynurenine pathway. The tumor cells, after an expressed high level of IDO by the inducing of interferon-γ (IFN-γ), exhibit the ability to cease T lymphocytes to proliferation and function because of the depletion of tryptophan surrounding the microenvironment. Furthermore, the tryptophan metabolites demonstrate the toxicity to lymphocytes, leading to the high IDO expressed tumor cells having the ability to be immune-escape.
Since the high levels of IDO-expressed tumor cells having the aptitude of immune escaping, we thus aimed at the preparation of the anti-IDO antibodies, including the polyclonal, monoclonal and scFv antibodies, hoping to neutralize the role of IDO in neoplasm and allow the patient's immune system to function. In this study, the IDO cDNA of human ovarian cancer cells (SKOV-3) was cloned into pET-28a plasmid. The human enzyme was over-expressed in Escherichia coli with hexahistidyl tag and purified with cobalt-agarose affinity chromatography. The anti-human IDO polyclonal antibody was obtained by immunizing mice with purified his-IDO protein and was used to detect the IDO presence in either SKOV-3 with high specificity. The monoclonal antibodies were also obtained with hybridoma technique. The cDNAs of variable regions of the heavy and light chain (VH and VL) of monoclonal antibody were obtained by RT-PCR of corresponding hybridoma cell. The DNA segment of the single chain fragment of variable region (scFv) antibody was also obtained by linking the VH and VL regions. Further studies, including scFv protein expression, bio-functional assays and animal model studies, are needed to proof the strategy being operational for anticancer therapy as supplemental medicine.
其他識別: U0005-0208201015575700
Appears in Collections:生物化學研究所

Show full item record

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.